A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
NCT02298387
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
71
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumor Malignancies
Interventions
DRUG:
OMP-305B83
Sponsor
OncoMed Pharmaceuticals, Inc.